Compare AAOI & GLPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AAOI | GLPG |
|---|---|---|
| Founded | 1997 | 1999 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Semiconductors | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.4B | 2.1B |
| IPO Year | 2013 | 2005 |
| Metric | AAOI | GLPG |
|---|---|---|
| Price | $38.11 | $33.03 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 4 |
| Target Price | ★ $33.60 | $31.33 |
| AVG Volume (30 Days) | ★ 5.5M | 99.8K |
| Earning Date | 02-25-2026 | 02-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $421,712,000.00 | $336,643,201.00 |
| Revenue This Year | $85.86 | $1.76 |
| Revenue Next Year | $64.48 | $0.49 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 101.25 | 10.31 |
| 52 Week Low | $9.71 | $22.36 |
| 52 Week High | $41.96 | $37.78 |
| Indicator | AAOI | GLPG |
|---|---|---|
| Relative Strength Index (RSI) | 58.77 | 59.23 |
| Support Level | $34.02 | $31.71 |
| Resistance Level | $41.35 | $33.91 |
| Average True Range (ATR) | 3.62 | 0.74 |
| MACD | 0.09 | 0.04 |
| Stochastic Oscillator | 76.25 | 69.44 |
Applied Optoelectronics Inc is a provider of fiber-optic networking products, for four networking end-markets; internet data center, CATV, telecom, and FTTH. The Company designs and manufactures a wide range of optical communications products at varying levels of integration, from components, subassemblies, and modules to complete turn-key equipment. Through direct sales personnel, and manufacturing teams in the United States, China, and Taiwan, the company coordinates with customers to determine product design, qualifications, and performance. The Company has manufacturing and research and development facilities located in the U.S., Taiwan, and China.
Galapagos NV is a fully integrated biotechnology company with operations in Europe and the United States, dedicated to developing medicines focusing on oncology and immunology. The group focuses on unmet medical needs, it synergizes compelling science, technology, and collaborative approaches to create a deep pipeline of medicines. Its clinical pipeline includes: GLPG5101, a CD19 CAR-T product candidate decentralized manufactured, currently in Phase 1/2 in rrNHL; GLPG5301, a BCMA CAR-T product candidate decentralized manufactured, currently in Phase 1 in rrMM; and GLPG3667, a TYK2 inhibitor currently in Phase 2 clinical trial in DM and SLE. It derives maximum revenue from the United States of America.